Search Results - "Comis, R."

A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer by Treat, J.A., Gonin, R., Socinski, M.A., Edelman, M.J., Catalano, R.B., Marinucci, D.M., Ansari, R., Gillenwater, H.H., Rowland, K.M., Comis, R.L., Obasaju, C.K., Belani, C.P.

“…Paclitaxel–carboplatin is used as the standard regimen for patients with advanced or metastatic non-small-cell lung cancer (NSCLC). This trial was designed to…”
Get full text

NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) trial: A novel public-private partnership by Chen, A, Conley, B, Hamilton, S, Williams, M, O'Dwyer, P, Arteaga, C, Gray, R, McShane, L, Li, S, Rubinstein, L, Patton, D, Sazali, K, Zwiebel, J, Mitchell, E, Smith, M.L, Dragaud, D, Little, R, Comis, R, Abrams, J, Flaherty, K

“…Background: The NCI MATCH is an efficacy signal-finding trial to identify molecular alterations that can be matched to targeted treatments in tumor biopsies…”
Get full text

Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis by Langer, C J, Leighton, J C, Comis, R L, O'Dwyer, P J, McAleer, C A, Bonjo, C A, Engstrom, P F, Litwin, S, Ozols, R F

“…To determine the activity and toxicity of combination paclitaxel (24 hours) and carboplatin in advanced non-small-cell lung cancer (NSCLC). Eligibility…”
Get more information

Oncologists' Use of Quality of Life Information: Results of a Survey of Eastern Cooperative Oncology Group Physicians by A. Bezjak, Ng, P., R. Skeel, A. D. De Petrillo, R. Comis, K. M. Taylor

“…Purpose: Objectives of this study were to obtain data from Eastern Cooperative Oncology Group (ECOG) oncologists regarding their views on quality of life (QOL)…”
Get full text

Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer by O'Dwyer, P J, Hamilton, T C, LaCreta, F P, Gallo, J M, Kilpatrick, D, Halbherr, T, Brennan, J, Bookman, M A, Hoffman, J, Young, R C, Comis, R L, Ozols, R F

“…Resistance to alkylating agents and platinum compounds is associated with elevated levels of glutathione (GSH). Depletion of GSH by buthionine sulfoximine…”
Get more information

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer by Hudes, G R, Greenberg, R, Krigel, R L, Fox, S, Scher, R, Litwin, S, Watts, P, Speicher, L, Tew, K, Comis, R

“…Estramustine phosphate (EMP) and vinblastine are two microtubule inhibitors with distinct molecular targets and at least additive antimicrotubule effects in…”
Get more information

Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group by Bonomi, P D, Finkelstein, D M, Ruckdeschel, J C, Blum, R H, Green, M D, Mason, B, Hahn, R, Tormey, D C, Harris, J, Comis, R

“…During the last decade, the Eastern Cooperative Oncology Group (ECOG) has studied a series of combination chemotherapy regimens in metastatic (stage IV)…”
Get more information

Molecular alterations to human chromosome 3p loci in neuroendocrine lung tumors by Kovatich, Albert, Friedland, David M., Druck, Teresa, Hadaczek, Piotr, Huebner, Kay, Comis, Robert L., Hauck, Walter, McCue, Peter A.

“…BACKGROUND The origins of and interrelations between low grade and high grade neuroendocrine lung tumors, typical and atypical carcinoids, and small cell lung…”
Get full text

Cisplatin: the future by Comis, R L

“…Cisplatin is one of the most important anticancer drugs yet developed. It proved critical in the development of curative programs for testicular cancer and in…”
Get more information

A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B by Chahinian, A P, Propert, K J, Ware, J H, Zimmer, B, Perry, M C, Hirsh, V, Skarin, A, Kopel, S, Holland, J F, Comis, R L

“…The Cancer and Leukemia Group B (CALGB) conducted a prospective randomized trial to evaluate the role of warfarin and alternating chemotherapy in extensive…”
Get more information

Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid by O'DWYER, P. J, LACRETA, F, NASH, S, TINSLEY, P. W, SCHILDER, R, CLAPPER, M. L, TEW, K. D, PANTING, L, COMIS, R. L, OZOLS, R. F

“…The glutathione transferases comprise a family of isoenzymes, one or more of which are involved in the conjugation of alkylating agents to glutathione (GSH)…”
Get full text

Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients by Spiegelman, D, Maurer, L H, Ware, J H, Perry, M C, Chahinian, A P, Comis, R, Eaton, W, Zimmer, B, Green, M

“…Cancer and Leukemia Group B (CALGB) accrued 1,745 patients with limited (LD) or extensive (ED) small-cell lung cancer (SCCL) to five separate trials between…”
Get more information

Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results by O'Dwyer, P J, Hamilton, T C, Young, R C, LaCreta, F P, Carp, N, Tew, K D, Padavic, K, Comis, R L, Ozols, R F

Get more information

The Cooperative Groups : Past and future by COMIS, R. L

“…The Cooperative Group system of the National Cancer Institute (NCI) has been in existence since the 1950s and has evolved to comprise 11 groups, the membership…”
Get full text

Future directions in the treatment of non-small cell lung cancer by Comis, R L, Finley, R S

“…In recent years significant advances have been made in the treatment of metastatic non-small cell lung cancer. These advances have been due to both the…”
Get more information

Socioeconomic status and cancer survival by Cella, D F, Orav, E J, Kornblith, A B, Holland, J C, Silberfarb, P M, Lee, K W, Comis, R L, Perry, M, Cooper, R, Maurer, L H

“…Survival data from eight Cancer and Leukemia Group B (CALGB) protocols were examined for patients with lung cancer (N = 961), multiple myeloma (N = 577),…”
Get more information

Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma by Prados, M D, Scott, C B, Rotman, M, Rubin, P, Murray, K, Sause, W, Asbell, S, Comis, R, Curran, W, Nelson, J, Davis, R L, Levin, V A, Lamborn, K, Phillips, T L

“…To examine the effect of treatment using Bromodeoxyuridine (BrdU) during radiation therapy on malignant glioma patient survival by comparing historical…”
Get more information

Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study by Wolff, A C, Ettinger, D S, Neuberg, D, Comis, R L, Ruckdeschel, J C, Bonomi, P D, Johnson, D H

“…A phase II study of ifosfamide, carboplatin, and prolonged oral administration of etoposide (ICE) in patients with untreated extensive-disease (ED) small-cell…”
Get more information

Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease by Cummings, F J, Kim, K, Neiman, R S, Comis, R L, Oken, M M, Weitzman, S A, Mann, R B, O'Connell, M J

“…Thirty-seven patients with refractory lymphoma or cutaneous T-cell lymphoma were treated with 2'-deoxycoformycin (pentostatin; dCF), 5 mg/m2 intravenous (IV)…”
Get more information

Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer by O'Dwyer, P J, Paul, A R, Walczak, J, Weiner, L M, Litwin, S, Comis, R L

“…Higher response rates in colorectal cancer have been observed with regimens that increase the cytotoxicity of fluorouracil (5-FU) by altering the biochemical…”
Get more information